Form 4: T2 Biosystems CFO John M. Sprague Reports Stock Transaction
SEC Form 4
Chief Financial Officer John M. Sprague of T2 Biosystems, Inc. reports a transaction involving restricted stock units on February 24, 2024.
Summary
- On February 24, 2024, John M. Sprague, the Chief Financial Officer of T2 Biosystems, Inc., reported a transaction.
- The transaction involved the disposition of 29 common stock shares related to the vesting of restricted stock units (RSUs).
- Following the transaction, Sprague directly owns 141 shares of T2 Biosystems common stock.
- The reported transaction was related to RSUs granted on February 24, 2021, which vest in three equal installments starting February 24, 2022.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 02/24/2021 | Reporting person was granted 87 RSU's that vest in three equal installments commencing on February 24, 2022 |
| 02/24/2022 | First vesting date of restricted stock units granted on February 24, 2021. |
| 02/24/2024 | Date of the reported transaction involving the disposition of 29 common stock shares due to RSU vesting. |
| 02/27/2024 | Date of signature on the Form 4 filing. |
Keywords
T2 Biosystems, Sprague, CFO, Form 4, Stock Transaction, Restricted Stock Units, TTOO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.